Literature DB >> 12951366

Macrophage cholesterol efflux and the active domains of serum amyloid A 2.1.

Robert Kisilevsky1, Shui Pang Tam.   

Abstract

Serum amyloid A 2.1 (SAA2.1) suppresses ACAT and stimulates cholesteryl ester hydrolase (CEH) activities in cholesterol-laden macrophages, and in the presence of a cholesterol transporter and an extracellular acceptor, there is a marked increase in the rate of cholesterol export in culture and in vivo. The stimulation of CEH activity by SAA2.1 is not affected by chloroquine, suggesting that it operates on neutral CEH rather than the lysosomal form. With liposomes containing individual peptides of SAA2.1, residues 1-20 inhibit ACAT activity, residues 74-103 stimulate CEH activity, and each of residues 1-20 and 74-103 promotes macrophage cholesterol efflux to HDL in culture media. In combination, these peptides exhibit a profound effect, so that 55-70% of cholesterol is exported to media HDL in 24 h. The effect is also demonstrable in vivo. [3H]cholesterol-laden macrophages injected intravenously into mice were allowed to establish themselves for 24 h. Thereafter, the mice received a single intravenous injection of liposomes containing intact SAA1.1, SAA2.1, peptides composed of SAA2.1 residues 1-20, 21-50, 51-80, 74-103, or SAA1.1 residues 1-20. Only liposomes containing intact SAA2.1 or its residues 1-20 or 74-103 promoted the efflux of cholesterol in vivo. A single injection of each of the active peptides is effective in promoting cholesterol efflux in vivo for at least 4 days.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12951366     DOI: 10.1194/jlr.M300133-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  14 in total

1.  Structure of serum amyloid A suggests a mechanism for selective lipoprotein binding and functions: SAA as a hub in macromolecular interaction networks.

Authors:  Nicholas M Frame; Olga Gursky
Journal:  FEBS Lett       Date:  2016-03-06       Impact factor: 4.124

Review 2.  HDL apolipoprotein-related peptides in the treatment of atherosclerosis and other inflammatory disorders.

Authors:  G S Getz; G D Wool; C A Reardon
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

3.  Impact of individual acute phase serum amyloid A isoforms on HDL metabolism in mice.

Authors:  Myung-Hee Kim; Maria C de Beer; Joanne M Wroblewski; Richard J Charnigo; Ailing Ji; Nancy R Webb; Frederick C de Beer; Deneys R van der Westhuyzen
Journal:  J Lipid Res       Date:  2016-03-27       Impact factor: 5.922

4.  Human serum amyloid A protein inhibits hepatitis C virus entry into cells.

Authors:  Zhaohui Cai; Lei Cai; Jieyun Jiang; Kyung-Soo Chang; Deneys R van der Westhuyzen; Guangxiang Luo
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

5.  Secretory phospholipase A2, group IIA is a novel serum amyloid A target gene: activation of smooth muscle cell expression by an interleukin-1 receptor-independent mechanism.

Authors:  Christopher P Sullivan; Stephanie E Seidl; Celeste B Rich; Michel Raymondjean; Barbara M Schreiber
Journal:  J Biol Chem       Date:  2009-10-22       Impact factor: 5.157

Review 6.  Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis.

Authors:  Luke J Leman; Bruce E Maryanoff; M Reza Ghadiri
Journal:  J Med Chem       Date:  2013-10-29       Impact factor: 7.446

7.  Cot/tpl2 participates in the activation of macrophages by adiponectin.

Authors:  Carlos Sanz-Garcia; Laura E Nagy; Miguel A Lasunción; Margarita Fernandez; Susana Alemany
Journal:  J Leukoc Biol       Date:  2014-02-14       Impact factor: 4.962

8.  Acute-phase-HDL remodeling by heparan sulfate generates a novel lipoprotein with exceptional cholesterol efflux activity from macrophages.

Authors:  Shui-Pang Tam; Robert Kisilevsky; John B Ancsin
Journal:  PLoS One       Date:  2008-12-05       Impact factor: 3.240

9.  Adipose tissue-derived human serum amyloid a does not affect atherosclerotic lesion area in hSAA1+/-/ApoE-/- mice.

Authors:  Sofie Ahlin; Maja Olsson; Anna S Wilhelmson; Kristina Skålén; Jan Borén; Lena M S Carlsson; Per-Arne Svensson; Kajsa Sjöholm
Journal:  PLoS One       Date:  2014-04-21       Impact factor: 3.240

10.  No evidence for a role of adipose tissue-derived serum amyloid a in the development of insulin resistance or obesity-related inflammation in hSAA1(+/-) transgenic mice.

Authors:  Sofie Ahlin; Maja Olsson; Bob Olsson; Per-Arne Svensson; Kajsa Sjöholm
Journal:  PLoS One       Date:  2013-08-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.